Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.

[1]  P. Poole‐Wilson,et al.  Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. , 2005, European heart journal.

[2]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[3]  Shing‐Jong Lin,et al.  Carvedilol Inhibits Tumor Necrosis Factor-&agr;–Induced Endothelial Transcription Factor Activation, Adhesion Molecule Expression, and Adhesiveness to Human Mononuclear Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[4]  Stephanie Läer,et al.  Carvedilol but Not Metoprolol Reduces β-Adrenergic Responsiveness After Complete Elimination From Plasma In Vivo , 2004, Circulation.

[5]  M. Hori,et al.  β-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts , 2004, Circulation.

[6]  松田 康章.  Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease , 2004 .

[7]  L. Rydén,et al.  The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN) , 2004, Cardiovascular Drugs and Therapy.

[8]  K. Hryniewicz,et al.  Comparative Effects of Carvedilol and Metoprolol on Regional Vascular Responses to Adrenergic Stimuli in Normal Subjects and Patients With Chronic Heart Failure , 2003, Circulation.

[9]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[10]  P. Macfarlane,et al.  Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial , 2003, The Lancet.

[11]  P. Oliveira,et al.  Impact of carvedilol on the mitochondrial damage induced by hypoxanthine and xantine oxidase--what role in myocardial ischemia and reperfusion? , 2002, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[12]  P. Poole‐Wilson,et al.  Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET , 2002, European journal of heart failure.

[13]  J. Berlin,et al.  Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. , 2001, American heart journal.

[14]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[15]  Klaus-DieterSchlüter.  β2-Adrenergic Receptor Overexpression Exacerbates Development of Heart Failure After Aortic Stenosis , 2001 .

[16]  A. Zeiher,et al.  Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. , 2000, Journal of the American College of Cardiology.

[17]  T. Yue,et al.  Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. , 2000, European journal of pharmacology.

[18]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[19]  H. Katus,et al.  Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. , 2000, Journal of cardiovascular pharmacology.

[20]  E. Schiffrin,et al.  Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. , 2000, Journal of cardiovascular pharmacology.

[21]  J. Mehta,et al.  Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. , 2000, Cardiovascular research.

[22]  A. Dart,et al.  beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. , 2000, Circulation.

[23]  L. Lind,et al.  Divergent effects of different beta-blocking agents on endothelium-dependent vasodilatation in the human forearm. , 2000, Blood pressure.

[24]  M. Metra,et al.  Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. , 2000, Circulation.

[25]  K. Woo,et al.  Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. , 1999, Journal of the American College of Cardiology.

[26]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[27]  L. Mestroni,et al.  Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol , 1999 .

[28]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[29]  L. Mestroni,et al.  Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. , 1999, Journal of the American College of Cardiology.

[30]  N. Khandoudi,et al.  Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury. , 1998, Journal of cardiovascular pharmacology.

[31]  G. Billman,et al.  Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. , 1997, Circulation.

[32]  R. Doughty,et al.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. , 1997, Journal of the American College of Cardiology.

[33]  R. Doughty,et al.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease , 1997 .

[34]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[35]  T. Yue,et al.  Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. , 1996, The Journal of pharmacology and experimental therapeutics.

[36]  E. Johns,et al.  Alpha-1 adrenoceptor subtypes involved in mediating adrenergically induced antinatriuresis and antidiuresis in two kidney, one clip Goldblatt and deoxycorticosterone acetate-salt hypertensive rats. , 1996, The Journal of pharmacology and experimental therapeutics.

[37]  T. Yue,et al.  Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. , 1995, Pharmacology.